- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.06. | Xilio Therapeutics erweitert Vorstand mit neuem Direktor | 2 | Investing.com Deutsch | ||
| 10.06. | Xilio Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors | 3 | GlobeNewswire (USA) | ||
| 06.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Closing of $50.0 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 03.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 83 | GlobeNewswire (Europe) | WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 02.06. | Xilio Therapeutics announces pricing of $50 million public offering | 2 | Seeking Alpha | ||
| 02.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 02.06. | Xilio Therapeutics announces public offering; shares down | 1 | Seeking Alpha | ||
| 02.06. | Xilio Therapeutics announces public offering of warrants | 1 | Investing.com | ||
| 02.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Proposed Public Offering | 2 | GlobeNewswire (USA) | ||
| 02.06. | Xilio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial | 3 | Insider Monkey | ||
| 31.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer | 62 | GlobeNewswire (Europe) | 26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses... ► Artikel lesen | |
| 08.05. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results | 183 | GlobeNewswire (Europe) | Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal... ► Artikel lesen | |
| 08.05. | Xilio Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 02.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 129 | GlobeNewswire (Europe) | WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 23.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ... | 2 | GlobeNewswire (USA) | ||
| 08.04. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 133 | GlobeNewswire (Europe) | WALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,113 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,907 | 0,00 % | Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST-Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 0,875 | -12,06 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,476 | -1,24 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| VAXART | 0,533 | +3,90 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,844 | -7,34 % | XFRA BNE0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,272 | +6,25 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split | FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 8,000 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Resumes Trading on NYSE American | OCALA, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that its common stock has resumed trading on the NYSE American under... ► Artikel lesen | |
| IMMUNIC | 0,638 | +0,31 % | EQS-News: Immunic AG: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,099 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 2,510 | +10,09 % | Pre-market Movers: Navitas Semiconductor, Longevity Health, CEL-SCI, Hyperscale Data, Sunrun | PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.35 A.M. ET).In the Green Navitas Semiconductor Corporation (NVTS) is... ► Artikel lesen |
XILIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,688 Euro und damit +3,88 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.